Drug Profile
Research programme: biosimilar monoclonal antibodies and protein therapeutics - Percivia
Latest Information Update: 20 Nov 2012
Price :
$50
*
At a glance
- Originator PERCIVIA
- Class Biobetters; Monoclonal antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 07 Aug 2012 Discontinued for Undefined indication in Netherlands (Parenteral)
- 22 Sep 2010 Investigation in Undefined indication in Netherlands (Parenteral)